CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CXCR4
mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-03
DOI
10.1111/bjh.16088
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia
- (2018) Jorge J. Castillo et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia
- (2018) Jorge J. Castillo et al. CLINICAL CANCER RESEARCH
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
- (2018) Romanos Sklavenitis-Pistofidis et al. BLOOD
- Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia
- (2017) Zachary R. Hunter et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis
- (2016) Adam J. Olszewski et al. ONCOLOGIST
- Clonal architecture ofCXCR4WHIM-like mutations in Waldenström Macroglobulinaemia
- (2015) Lian Xu et al. BRITISH JOURNAL OF HAEMATOLOGY
- MYD88L265P andCXCR4mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
- (2015) Janine Schmidt et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genomic Landscape of CXCR4 Mutations in Waldenstro m Macroglobulinemia
- (2015) S. Poulain et al. CLINICAL CANCER RESEARCH
- Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
- (2015) M. F. M. de Rooij et al. HAEMATOLOGICA
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
- (2015) M. F. M. de Rooij et al. HAEMATOLOGICA
- C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
- (2014) A. M. Roccaro et al. BLOOD
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- CXCR4WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplantMYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells
- (2014) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia
- (2014) Y Cao et al. LEUKEMIA
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
- (2013) Z. R. Hunter et al. BLOOD
- MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
- (2013) L. Xu et al. BLOOD
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
- (2012) Roger G. Owen et al. BRITISH JOURNAL OF HAEMATOLOGY
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
- (2011) L. Dotta et al. CURRENT MOLECULAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now